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Psychomotor retardation has been recognized as a principal component of depression for cen-
turies. Amongst symptoms and signs associated with depression, it is seen as having high
predictive validity, correlating with severity of illness and the outcome of numerous thera-
peutic interventions. Of the two components—”psycho” and “motor”—the psychological com-
ponent has received the most thorough investigation and has been given the greatest con-
sideration. The “motor” (or motion) component has been given little consideration. A review
of the literature suggests few studies have attempted to quantitatively characterize this phe-
nomenon or use it as anything more than one indice among other signs and symptoms of de-
pression. Unlike other phenomena associated with depression, the use of motion alterations
has lagged in significance due to limited technology that would allow its study; depression
has been seen predominantly as a “mood” disorder, with principal interest being in the “feel-
ings” associated with the disorder. Recent advances in motion capture technologies allow mo-
tion alterations to be used for many purposes, both quantitative and qualitative. These sources
of information appear to have direct and indirect impact. There is a fertile future for motion
capture constructs in the study of depression, and recent technological advances will allow
progress to occur in this area.
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INTRODUCTION
THE PRINCIPAL CHARACTERISTICS of depressionhave been known for a number of cen-
turies.1–3 Foremost amongst the symptoms has
been psychomotor alterations, particularly ev-
idenced by slowing during an episode and a
return to normal after a resolution of the
episode. Psychomotor slowing has been shown
to correlate with the degree of depression and
the onset of depression.4–6,17 Psychomotor
slowing has also been found to occur with
greater frequency with various subtypes: bipo-
lar versus unipolar; endogenous versus nonen-
dogenous; psychotic versus nonpsychotic; and
vascular versus nonvascular.9–13 Also, re-
sponse to therapeutic interventions, including
electroconvulsive therapy, has been correlated
with motor slowing.14 Some have postulated,
given the significance of the motor slowing,
that depressive illnesses are in fact movement
disorders, not mood disorders.15,16
Compared to other symptoms and signs as-
sociated with depression, psychomotor alter-
ations have not received extensive study or at-
tention. Symptoms most frequently studied
have been alterations in sleep, cognition, ap-
petite, and sexual desire. In large part, psy-
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chomotor retardation research has primarily
focused on the cognitive alterations associated
with depression, i.e., decreased concentration,
forgetfulness, and indecisiveness. The motor
component has rarely been dealt with. An ex-
ception has been the work of Parker and col-
leagues, who have pursued psychomotor al-
terations and have developed a methodology
to understand the significance of motor alter-
ations. They have developed an observation-
based instrument (CORE) that codifies the
presence of psychomotor alterations amongst
depressed patients.17–20 CORE enables one to
measure the severity of psychomotor phenom-
ena in patients and to arrange types of motor
alterations into three groups: retardation, agi-
tation, or noninteractiveness. Using CORE,
they have been able to predict response to treat-
ment intervention and treatment outcome.21
Certainly Parker’s work adds to the validity of
the significance of motor alterations in depres-
sion and the justification for more aggressive
research to determine its relevance.
PREVIOUS APPLIED MOTION
TECHNOLOGY STUDIES
Given the significance of motor alterations in
depression, one would expect that there would
have been more studies with this as a primary
focus. In fact, there are few. Certainly, those uti-
lizing technologies to reflect motion alterations
have been limited. In part, this may be ex-
plained on the basis of limited technologies that
would allow a more quantitative or qualitative
characterization of motor alterations. Studies
that have attempted to characterize motor
slowing have employed facial electromyo-
grams, speech pause time, gross motor analy-
sis, and gait analysis.21–29 All these techniques
revealed that the motor component of psy-
chomotor retardation could be characterized
and did differentiate depressed from normal
subjects, yet the studies have been rarely cited.
One would have to assume that either motor
alterations have little significance or the tech-
nologies used provide little additional insight
than one could gain through observation. If
that is the case, which might be true in the in-
stances mentioned, then one could understand
why little research has occurred in this area.
Others have expressed an interest in the lack of
progress in this area and emphasized its im-
portance for future research.53
Currently, there does not exist a frame of ref-
erence for discourse concerning the use of mo-
tion technologies. When the topic arises, the
most frequently asked questions are: Can’t the
same data be derived from clinical observa-
tions? Aren’t our current rating scales suffi-
cient? Couldn’t video be used, and wouldn’t it
serve the same purpose? What can be gained
by using motion capture technology? These are
reasonable questions. In fact, it is unclear what
might have been gained using older technolo-
gies, the advent of digital motion capture tech-




Motion capture technology is not new. The
first attempts to capture motion took place in
the late 19th century. This was at a time when
“motion pictures” were being invented, and
there was interest as to how best create them
and determine what they might show. Muy-
bridge was a leader in this field.31 He used mul-
tiple cameras that took a sequence of photos as
an object moved to trip the shutter of an array
of cameras. These images were then shown in
such a way as to create motion. Digital motion
capture technology, in some ways, is very sim-
ilar to these early attempts at capturing motion.
Digital motion technology allows the acquisi-
tion of information about an object moving in
space at rates of 60 Hz per second, if not faster.
If a number of sensors/reflectors are placed on
a complex object such as the human form or
face, then information can be acquired about
that complex object moving in space and time.
Fundamentally, it is faster and more accurate,
and allows the data to be used in ways that pre-
viously had not been imagined, given that it
can be used to create objects in three-dimen-
sional space.
One of the foremost properties of digital data
is its accuracy. Given that motion capture tech-
nology systems can capture data at a rate of 60
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Hz per second from 36 sensors with an accu-
racy of 1 mm, the collected data is more accu-
rate than any data that can be captured by hu-
mans using any other means. This information
can serve both for quantitative analytic pur-
poses and qualitative purposes in the con-
struction of animated figures, avatars, or inter-
active virtual humans.
To date, motion capture data has found its
greatest applications in the areas of biome-
chanics, simulated digital virtual humans in
design, and animation.30,40 Such utilization of
data has never occurred in psychiatry despite
the vast amount of research data supporting
the notion that major alterations in motion oc-
cur involving the body and the face as core
symptoms and signs in disorders such as de-
pression, mania, and schizophrenia. Authors
have speculated as to the potential of this tech-





Offered here is a view of the potential of dig-
ital motion capture technology addressing the
previously stated questions.
Can’t the same data be derived from observation?
For some, the most fundamental question is,
“Does motion capture technology offer any
data that is not already being provided via a
standard clinical session?” This question con-
tains two elements: (1) Aren’t our observations
accurate enough? (2) Aren’t our methods of
documentation accurate enough? In fact, our
current diagnostic system is heavily dependent
on “subjective clinical observations,” which
have not been standardized. These observa-
tions are recorded in such a manner that they
provide the minimal amount of data about a
clinical situation. It is not clear that this data is
enough.
Aren’t our current rating scales sufficient?
Clinicians rarely use rating scales during the
treatment of depression. Issues such as sever-
ity lack operational definitions that are ac-
cepted and uniformly applied in the care of pa-
tients. True there are standardized diagnostic
criteria for major mood disorders. Neverthe-
less, it is not clear that these criteria are fol-
lowed rigorously, in the making of the diag-
nosis, in the documentation of the presence or
absence of signs and symptoms of depression,
or in the selection of therapeutic interventions.
This may have as much to do with the weak-
ness of the conceptual construct underlying
these definitions as with the lack of applied
rigor in the delivery of clinical care to these pa-
tients. Nevertheless, the fact that rating scales
are not widely used suggests the limited util-
ity of these instruments.
How might a digital motion capture system
augment a clinician’s encounter with a patient?
When clinicians first meet a patient, often they
are struck by the patient’s affect and move-
ment. This is before a single word is spoken.
Yet, it is often enough time for a skilled clini-
cian to begin the development of a differential
diagnosis and to determine therapeutic plan-
ning. This can happen within seconds of when
a patient enters a clinician’s office. A digital
motion capture system has the potential to cap-
ture the same data, similarly within seconds,
and objectively record this data for future use.
No clinician, no human has that potential. Hu-
mans do a wonderful job of recognizing a pat-
tern that is presented to them, but they have
limited capabilities in disaggregating that pat-
tern at the level that a digital motion system
would allow. Further, humans have fallible
memory. How many clinicians can recall with
accuracy their first encounter with a depressed
patient 10 years ago, 5 years ago, 1 year ago, or
even 1 month ago? A digital motion capture
system does not forget, nor does it alter the data
it captures.
Digital motion capture technology could
open a doorway to data that is objective much
as an electrocardiogram or other clinical labo-
ratory tests do. Certainly, the quest for an ob-
jective clinical marker of depression has been
the goal for many years of countless clinical re-
searchers. These researchers have primarily
looked to biochemical, endocrinological, and
neurobiological phenomena as potential clini-
cal markers. To date, there is no proven clini-
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cal “state” marker that is used by clinicians to
characterize depression. The primary reason that
no marker is used is because there is a lack of ro-
bust correlation to provide clinicians with cer-
tainty in its application. Digital motion capture
data could prove more robust, and since it is not
a biomarker, dependent on an alteration of a pre-
sumed pathophysiological perturbation, it
would likely provide a more valid reflection of
the disease state itself. Digital motion capture
data would also prove to be highly accurate, and,
since it can be recorded in digital form, it can be
used for future analytic comparisons. Therefore,
the more robust, valid, accurate, and storable
digital motion capture data could ultimately be
more valuable than clinical observation alone.
Couldn’t video be used, and wouldn’t it serve the
same purpose?
Video offers both advantages and disadvan-
tages as compared to digital motion capture.
They both make recordings that, in principle,
are more accurate than human observations
alone, and both these recordings can be stored
for future reference. Video has the advantages
of being relatively inexpensive and widely
available, though price and availability would
undoubtedly change if the market for digital
motion technologies grew. Digital motion tech-
nology has the advantages of providing a data-
base that can be reused for a number of differ-
ent purposes. Quantitatively, the data can be
used in a number different analytic situations.
No such type of data results from a video
recording. Qualitatively, the data can be used
to reconstruct virtual humans that would ap-
pear similar to the patient or, if so desired, as
another individual. Certainly, a video record-
ing could never serve this purpose. Video pro-
duces a two-dimensional representation of the
phenomena that it is recording or broadcasting.
Digital motion technology can be used to pro-
duce three-dimensional objects as well as two-
dimensional objects. Tele-immersion is one of
the potential applications of this data. Lastly,
video recordings are extremely difficult to
structure for subsequent utilization; i.e., search-
ing the video for specific information about a
patient’s condition would be extremely diffi-
cult, even using digital video.
What can be gained by using a digital motion
capture technology?
There are direct and indirect gains to be
made by using digital motion capture technol-
ogy. Direct gains include the accuracy previ-
ously mentioned and its reuse for both quanti-
tative and qualitative purposes. Indirect gains
include an increased emphasis on motion as a
principal component of depression as com-
pared to emotion.
Quantitative reuse of the resulting digital
data would allow for the potential “decon-
struction” of the concept of psychomotor re-
tardation. Velocity or acceleration of each body
segment could be calculated, or a summation
of the body could be determined. Angular ve-
locity and acceleration could be calculated for
each joint. This data, in total, would allow for
much greater insight into what constitutes the
most significant elements of psychomotor re-
tardation. Biomechanical calculations could be
made to better understand the relationship of
depression with lower back pain, especially
amongst those who do repetitive, physically
taxing tasks such as lifting.55 Given the poten-
tial sensitivity and accuracy of the measures,
they may prove of value in the characterization
of chronic, severe refractory depressive disor-
ders and in tracking treatment response, re-
mission, and relapse.
Qualitative reuse of the digital data would
allow for the development of avatars or virtual
humans. These virtual humans could prove to
be of value in educating the public about se-
vere depressive illnesses. It has been asked,
“How could virtual humans prove to be of
greater value than videotapes of depressed pa-
tients?” First, one has to realize that there exist
few videotapes of people with depression.
Since few videos exist, one has to conclude that
there is a reason. One speculation is that pa-
tients with these disorders do not want to be
videotaped due to issues of confidentiality and
privacy. It is here that virtual humans may
prove to have enormous potential. A digital
motion capture system could provide the
movement constructs that would be used to an-
imate a “virtual psychiatric patient.” This vir-
tual psychiatric patient would look and act like
a depressed patient, yet the appearance of the
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patient could be altered so that it did not ap-
pear like the patient from whom the data orig-
inated. This would be accomplished by chang-
ing the digital appearance of the patient. The
patient would be able to maintain privacy and
confidentiality while sharing with the world
the experience of having the illness. Such ap-
plications have not occurred yet, but it is only
a matter of time before such applications occur.
The principal indirect gain of the use of dig-
ital motion capture technology is a shift from
emotion to motion as the principal phenome-
non of depression. Current diagnostic systems
emphasize not only the primacy of the emotion
of sadness, feeling blue, or being down, but
they allow the subtyping of endogenous de-
pression to be made based on the distinct qual-
ity of depression. There is no subtyping based
on severity or degree of motion alteration. The
Diagnostic and Statistical Manual, 4th ed. (DSM-
IV), Hamilton Depression Rating Scale, and the
Zung Depression Rating Scale all have limited
reference to alterations in motion.33–35 One of
the most significant implications of motion be-
ing central in both representation and patho-
physiology of depression is a need to study
those factors whose alteration result in the ill-
ness. Given the primacy of emotion, most in-
vestigations and research of the last 20 years
have focused on discovering the underlying
neural mechanisms and systems responsible
for the creation, modulation, and, potentially,
the disruption of emotions. Norepinephrine
and serotonin have been identified as the prin-
cipal neurotransmitters responsible for depres-
sion, and many, if not most, of our psycho-
pharmacology agents operate in such a way as
to increase central levels of norepinephrine and
serotonin.
Structural or neurotransmission pathway
disruptions are two different conceptual mod-
els that might explain the pathophysiology of
motion alterations seen in depression. Imaging
studies of disorders with basal ganglia abnor-
malities show structural lesions, suggesting
disruption of the circuits connecting basal gan-
glia to prefrontal and anterior cingulated 
cortex resulting in apathy, dystonia, and de-
pression.56–58 Perfusion studies show reduced
levels of cerebral blood flow in paralimbic re-
gions, including the inferior frontal, anterior
cingulated, and anterior temporal cortex.59–61
Despite most studies focusing on norepineph-
rine and serotonin, there are studies that sup-
port a dopamine component. These have dem-
onstrated reductions of homovanillic (HVA)
acid, a metabolite of dopamine in the cere-
brospinal fluid of depressed patients.62–65 An-
tidepressants that are dopamine agonists have
been shown to be effective in those with de-
pression, substantiating the potential role of
dopamine.66–68 A number of genetic studies of
depressed patients have shown an association
with dopamine receptor genes.70,71
If motion could be better characterized, and
if it served to identify a subtype of depression
what might be the implications? Imaging stud-
ies could be developed that focused specifically
on the dopamine areas of the brain such as the
basal ganglia. Genetic studies could be devel-
oped to study dopamine transporter gene and
its alteration in families in which depression
appeared to be significantly represented.69 If
motion were a consideration, how might we
deal with the treatment of those with depres-
sion? Might we recommend physical rehabili-
tation rather than mental rehabilitation?
CONCLUSION
Digital motion capture technologies have
promise, as compared to previous motion char-
acterization technologies, which have been
used to characterize psychomotor retardation
in psychiatric research. Accuracy, stability,
storage, and reuse make it superior to all other
technologies used in this area before. Questions
about its value appear to be based on a lack of
knowledge concerning digital motion capture
technologies in general and their use in other
industries. With time, these technologies may
prove to be valuable in the areas of research,
clinical care, education, and communication
about depression.
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